KalVista Pharmaceuticals, Inc. - Common Stock (KALV)
12.45
+0.02 (0.16%)
Kalvista Pharmaceuticals Inc is a biopharmaceutical company focused on developing innovative therapies for diseases involving proteins called "kinases," which play a crucial role in various cellular processes
The company specializes in creating small molecule drugs aimed at treating chronic and rare diseases, particularly in areas such as ophthalmology and hereditary angioedema. With a commitment to employing advanced drug design and development techniques, Kalvista aims to address unmet medical needs and improve patient outcomes through its targeted therapeutic approaches.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
